thalidomide has been researched along with Duodenal Diseases in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).
Excerpt | Relevance | Reference |
---|---|---|
"Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
"Postoperative pathology confirmed Crohn's disease." | 1.48 | [The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula]. ( Guo, F; Li, JN; Li, XQ; Ma, ZQ; Qian, JM; Wang, YN; Xue, HD; Yang, AM; Zhou, WX, 2018) |
"Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Wang, YN | 1 |
Li, XQ | 1 |
Guo, F | 1 |
Yang, AM | 1 |
Qian, JM | 1 |
Li, JN | 1 |
Xue, HD | 1 |
Zhou, WX | 1 |
Ma, ZQ | 1 |
Nagano, S | 1 |
Mori, M | 1 |
Kato, A | 1 |
Ono, Y | 1 |
Aoki, K | 1 |
Arima, H | 1 |
Takiuchi, Y | 1 |
Tabata, S | 1 |
Yanagita, S | 1 |
Matsushita, A | 1 |
Ishikawa, T | 1 |
Imai, H | 1 |
Takahashi, T | 1 |
2 other studies available for thalidomide and Duodenal Diseases
Article | Year |
---|---|
[The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula].
Topics: Anastomosis, Surgical; Colon; Crohn Disease; Cutaneous Fistula; Digestive System Surgical Procedures | 2018 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |